NCT00417196已完成1 期
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Single Escalating Doses of Intravenous QAX576
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 32
- 试验地点
- 2
- 主要终点
- Safety and tolerability of single escalating doses of QAX576 as assessed by vital signs, electrocardiogram (ECG), adverse events, laboratory evaluations, up to 96 hours after drug administration, and telemetry up until 24 hours post dose
研究概览
简要总结
This study is designed to evaluate the safety, pharmacodynamic and pharmacokinetic effects of individual escalating intravenous doses of QAX576 in healthy volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and female subjects age 18 to 45 years, inclusive, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.
- •Only surgically sterilized female subjects with procedure performed at least 6 months prior to screening with supportive clinical documentation are allowed to participate in this study.
- •Male subjects must be using a double-barrier local contraception, i.e., spermicidal gel plus condom, for the entire duration of the study, up to Study Completion visit (i.e., refrain from fathering a child in the 4 months following last study drug administration).
- •Vital signs should be within the following ranges:
- •Oral body temperature 35.0-37.5°C. Supine systolic blood pressure, 90-140 mm Hg. Supine diastolic blood pressure, 50-90 mm Hg. Supine pulse rate, 50-90 beats per minute (bpm).
- •When blood pressure and pulse will be taken again after 3 minutes standing, there shall be no more than a 20 mm Hg drop in systolic or 10 mm Hg drop in diastolic blood pressure and increase in heart rate (>20 bpm) associated with clinical manifestation of postural hypotension.
- •Body mass index (BMI) must be within the range of 18 to 28 kg/m
- •Subjects must weigh between 50 and 100 kg (inclusive).
排除标准
- •Smokers (use of tobacco products in the previous 3 months). Smokers will be who reports tobacco use or has a urine cotinine greater than 500 ng/mL.
- •Use of any prescription drugs within 4 weeks prior dosing, or over-the-counter (OTC) medication (vitamins, herbal supplements, dietary supplements) within 2 weeks prior to dosing. Acetaminophen is acceptable with clinical documentation.
- •Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulations, and for any other limitation of participation based on local regulations.
- •Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing, or longer if required by local regulation.
- •Significant illness within 2 weeks prior to dosing.
- •A past medical history of clinically significant ECG abnormalities.
- •History of autonomic dysfunction or acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated) or clinically significant drug allergy or history of atopic allergy (asthma, urticaria, eczematous dermatitis). A known hypersensitivity to the study drug or drugs similar to the study drug..
- •History or presence of any surgical or medical condition which, in the opinion of the investigator, may jeopardize the subject in case of participation in the study, including hepatic, hematological, or immunological, disorders..
- •History of clinical schistosomiasis or travel within the preceding 6 months to an area with endemic schistosomiasis, including but not limited to Southeast Asia and Northwest Africa
- •Other protocol-defined inclusion/exclusion criteria may apply
结局指标
主要结局
Safety and tolerability of single escalating doses of QAX576 as assessed by vital signs, electrocardiogram (ECG), adverse events, laboratory evaluations, up to 96 hours after drug administration, and telemetry up until 24 hours post dose
次要结局
- Exploration of pharmacokinetics of QAX576 and its pharmacodynamic effects on interleukin 13 (IL-13) concentration data. Samples collection at pre-dose and up to 48 hours post-dose.
- Assess the immunogenicity of QAX576 in healthy subjects.
研究者
研究点 (2)
Loading locations...
相似试验
终止
4 期
A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic DisorderPanic DisorderNCT00635531Pfizer's Upjohn has merged with Mylan to form Viatris Inc.16
已完成
1 期
Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With StatinsLDL CholesterolHypercholesterolemiaNCT01859455Novartis Pharmaceuticals25
已完成
1 期
A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque PsoriasisPlaque PsoriasisNCT04594928Galapagos NV30
招募中
1 期
A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RS-C1001 Tablets in Chinese Healthy SubjectsDyslipidemiaNCT0666942972
已完成
2 期
A Safety PK/PD Study of SLV337 in Patients With Type 2 DiabetesType 2 DiabetesNCT00924534Abbott Products61